Merck & Co Inc
NYSE:MRK
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
96.31
132.96
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Merck & Co Inc
Wall Street
Price Targets
MRK Price Targets Summary
Merck & Co Inc
According to Wall Street analysts, the average 1-year price target for
MRK
is 131.54 USD
with a low forecast of 101 USD and a high forecast of 162.75 USD.
MRK Last Price Targets
Merck & Co Inc
The latest public price target was made on Nov 15, 2024 by
Akash Tewari
from
Jefferies
,
who expects
MRK
stock to
rise by 51%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Akash Tewari
Jefferies
|
148
USD
Upside 51% |
1 month ago
Nov 15, 2024
|
Merck (MRK) PT Raised to $148 at Jefferies
StreetInsider
|
Evan David Seigerman
BMO Capital
|
136
USD
Upside 38% |
1 month ago
Nov 1, 2024
|
Merck (MRK) PT Lowered to $136 at BMO Capital
StreetInsider
|
Trung Huynh
UBS
|
136
USD
Upside 38% |
2 months ago
Oct 9, 2024
|
Merck price target lowered to $136 from $142 at UBS
TheFly
|
Carter Gould
Barclays
|
140
USD
Upside 42% |
2 months ago
Oct 7, 2024
|
Merck price target lowered to $140 from $142 at Barclays
TheFly
|
|
Akash Tewari
Jefferies
|
147
USD
Upside 50% |
4 months ago
Aug 15, 2024
|
Merck (MRK) PT Lowered to $147 at Jefferies
StreetInsider
|
Geoff Meacham
Bank of America Securities
|
145
USD
Upside 48% |
4 months ago
Jul 31, 2024
|
Merck price target lowered to $145 from $150 at BofA
TheFly
|
|
Colin Bristow
UBS
|
142
USD
Upside 44% |
4 months ago
Jul 31, 2024
|
Merck Analysts Slash Their Forecasts After Q2 Results
Benzinga
|
Mohit Bansal
Wells Fargo
|
140
USD
Upside 42% |
6 months ago
Jun 12, 2024
|
Wells Fargo Reiterates Equal Weight Rating on Merck (MRK)
StreetInsider
|
|
Evan David Seigerman
BMO Capital
|
148
USD
Upside 51% |
6 months ago
May 30, 2024
|
BMO Capital Reiterates Outperform Rating on Merck (MRK)
StreetInsider
|
Unknown Analyst
Truist Financial
|
142
USD
Upside 44% |
8 months ago
Mar 27, 2024
|
Merck (MRK) PT Raised to $142 at Truist Securities
StreetInsider
|
|
Mohit Bansal
Wells Fargo
|
135
USD
Upside 37% |
8 months ago
Mar 27, 2024
|
Merck (MRK) PT Raised to $135 at Wells Fargo
StreetInsider
|
|
Akash Tewari
Jefferies
|
145
USD
Upside 48% |
8 months ago
Mar 27, 2024
|
Merck (MRK) PT Raised to $145 at Jefferies, 'modeling a strong launch out of the gate' for Winrevair
StreetInsider
|
Evan David Seigerman
Loop Capital Markets
|
132
USD
Upside 34% |
1 year ago
Nov 22, 2023
|
Merck's Caraway Deal: Analyst Says "Timely, Anchored By Novel Programs & Management Team"
Benzinga
|
Jay Olson
Oppenheimer
|
294
USD
Upside 199% |
1 year ago
Apr 12, 2023
|
These 3 Health Care Stocks Delivering High-Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts
Benzinga
|
Unknown Analyst
Morgan Stanley
|
99
USD
Upside 1% |
1 year ago
Feb 3, 2023
|
Morgan Stanley Maintains Equal-Weight on Merck & Co, Lowers Price Target to $99
Benzinga
|
|
Unknown Analyst
Wells Fargo
|
120
USD
Upside 22% |
1 year ago
Feb 3, 2023
|
Wells Fargo Maintains Overweight on Merck & Co, Lowers Price Target to $120
Benzinga
|
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is MRK's stock price target?
Price Target
131.54
USD
According to Wall Street analysts, the average 1-year price target for
MRK
is 131.54 USD
with a low forecast of 101 USD and a high forecast of 162.75 USD.
What is Merck & Co Inc's Revenue forecast?
Projected CAGR
6%
For the last 8 years the
compound annual growth rate for
Merck & Co Inc's revenue is
5%.
The projected
CAGR
for the next 4 years is
6%.
What is Merck & Co Inc's Operating Income forecast?
Projected CAGR
69%
For the last 8 years the
compound annual growth rate for
Merck & Co Inc's operating income is
-9%.
The projected
CAGR
for the next 4 years is
69%.
What is Merck & Co Inc's Net Income forecast?
Projected CAGR
199%
For the last 8 years the
compound annual growth rate for
Merck & Co Inc's net income is
-27%.
The projected
CAGR
for the next 4 years is
199%.
You don't have any saved screeners yet
